Veteran Biopharma Exec Tries to Fund His Own ProductAugust 18, 2017 |
And sees firsthand how hard it is. Galvanized by his teenage son’s epilepsy diagnosis, Mayes started a new company to try to shepherd a promising inhaler technology for epilepsy through a key clinical trial
Quick Read
How an unusual medical case in the 1990s provided a clue for how to treat a fatal muscle disease
Quick Read
A new paper in the latest issue of Health Affairs is worth a look. “Drugs Cleared Through The FDA’s Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process“
Quick Read
Stacey Lee, an assistant professor at JHU’s Carey Business School, suggests a more transparent process for patients
Quick Read
Latinos Left Out Of Clinical Trials … And Possible CuresJuly 19, 2017 |
“Only less than 8 percent of enrollees are Hispanic, even though Hispanics comprise 17 percent of the population,” said Dr. Eliseo Pérez-Stable, director of NIH’s National Institute on Minority Health and Health Disparities
Quick Read
Nolan and Jack Willis and just 10 other boys took part in a clinical trial that led to the approval last fall of the very first drug to treat their rare, deadly muscle disease. Now the Willis boys are again test cases as a different type of medical question comes to the fore: whether insurers will cover the controversial drug, Exondys 51, which can cost more than $1 million a year even though it’s still unclear if it works
Quick Read
In the summer of 2015, Alexandra Franco got a letter in the mail from a company she had never heard of called AcurianHealth. The letter, addressed to Franco personally, invited her to participate in a study of people with psoriasis, a condition that causes dry, itchy patches on the skin
Quick Read
Failure to WarnJune 6, 2017 |
Hundreds died while taking an arthritis drug, but nobody alerted patients. This is the first of two stories by STAT on monitoring the safety of new drugs
Quick Read
